Rome

• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel … Ended recruitment
  2024-511637-35-00 5 2021-03-23 Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
• Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended recruitment
  2024-518909-18-00 5 2021-03-23 HIV-1 infected individuals currently taking an INSTI-based three-drug
• Inebilizumab efficacy and safety in adults with myasthenia gravis Ended recruitment
  2023-510006-40-00 5 2021-03-22 Myasthenia Gravis which is either due to acetylcholine receptor antibo
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar … Ended recruitment
  2024-516632-99-00 4 2021-03-17 Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian
• An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance … Ended recruitment
  2022-502600-79-00 4 2021-03-16 Endometrial cancer
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended recruitment
  2023-507418-28-00 4 2021-03-15 Solid tumors
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended recruitment
  2023-505835-11-00 5 2021-03-12 Chronic Migraine
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended recruitment
  2023-505836-36-00 5 2021-03-12 Migraine
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended recruitment
  2022-502705-15-00 5 2021-03-08 High-risk muscle-invasive bladder cancer
• CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended recruitment
  2024-519174-39-00 7 2021-02-15 Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Lar
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended recruitment
  2022-503073-11-00 5 2021-02-13 Stage IIIb cardiac AL amyloidosis
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatr … Ended recruitment
  2024-512889-33-00 4 2021-01-30 HIV-1 Infection
• DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o … Ended recruitment
  2023-505309-18-00 9 2021-01-21 HER2-positive Metastatic Breast Cancer
• A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of son … Ended recruitment
  2024-516797-29-00 4 2021-01-12 locally advanced basal cell carcinoma
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended recruitment
  2024-513616-95-00 10 2020-12-22 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended recruitment
  2023-504959-27-00 5 2020-12-09 Participants with Limited Stage-Small Cell Lung Cancer, who have recei
• The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing Tumors Ended recruitment
  2023-504721-39-02 4 2020-12-07 HER2 Expressing Tumors
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT

Showing 1,513–1,536 of 2,096 trials